"We do not seek conflict with Iran or any other country," Trump tells reporters in the Oval Office.Politicsread more
Stocks in Asia were tepid in Tuesday morning trade, while investors looked toward to a meeting between U.S. President Donald Trump and Chinese President Xi Jinping set to...Asia Marketsread more
Chinese Vice Premier Liu He held a phone conversation with U.S. Trade Representative Robert Lighthizer and U.S. Treasury Secretary Steven Mnuchin, China's Ministry of Commerce...World Economyread more
U.S. President Donald Trump's senior adviser Kellyanne Conway will not testify before the House of Representatives Oversight Committee this week on her alleged violations of...Politicsread more
(Adds background, details on other regulators position, share graph)
May 28 (Reuters) - Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country's health agency suspended the company's licenses for the implants, citing increased risk of cancer.
The Botox-maker in December took its textured breast implants off the market in Europe after a French regulatory body ordered a recall.
Textured breast implants, which have a rough surface and are more commonly used in Europe than in the United States, have been linked to a rare type of cancer known as breast-implant associated anaplastic large cell lymphoma (BIA-ALCL).
The potential risks associated with the implants outweigh their benefits, including the rare but serious risk of BIA-ALCL, Health Canada said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reu t e r s . c o m : 2 0 1 9 0 5 2 8 : n C N W z f k N p a on Tuesday.
Health Canada's decision is in contrast to public rulings and positions by other regulatory bodies around the world, including the U.S. Food and Drug Administration's (FDA) recent position, Allergan said.
The FDA said in May it would not ban textured breast implants at this time as it investigates the implant and raises awareness related to safety of these devices.
The recall does not impact Natrelle smooth implants, Allergan said, adding it would explore options to appeal the Canadian health regulator's decision.
Shares of the drugmaker closed down 3% at $131.4 on Tuesday. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)